Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

LY9 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

LY9 overexpression (1)

LY9 overexpression (1)

›

LY9 expression	Chronic Lymphocytic Leukemia	LY9 expression	Chronic Lymphocytic Leukemia	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D
LY9 expression	Mantle Cell Lymphoma	LY9 expression	Mantle Cell Lymphoma	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D
LY9 expression	Burkitt Lymphoma	LY9 expression	Burkitt Lymphoma	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D
LY9 expression	Diffuse Large B Cell Lymphoma	LY9 expression	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D
LY9 expression	Chronic Lymphocytic Leukemia	LY9 expression	Chronic Lymphocytic Leukemia	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D